Tumor-stroma ratio in the primary tumor is a prognostic factor in early breast cancer patients, especially in triple-negative carcinoma patients

Breast Cancer Research and Treatment

Volumn 125, Issue 3, 2011, Pages 687-696

  De Kruijf, Esther M ^a   Van Nes, Johanna G H ^a   Van De Velde, Cornelis J H ^a   Putter, Hein ^a   Smit, Vincent T H B M ^a   Liefers, Gerrit Jan ^a   Kuppen, Peter J K ^a   Tollenaar, Rob A E M ^a   Mesker, Wilma E ^a  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Breast cancer; Prognosis; Stroma; Triple negative carcinomas

Indexed keywords

ADULT; ARTICLE; BREAST CANCER; CANCER HORMONE THERAPY; CANCER STAGING; CANCER SURGERY; CARCINOMA; COHORT ANALYSIS; CONTROLLED STUDY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; REPRODUCIBILITY; RETROSPECTIVE STUDY; STROMA; TRIPLE NEGATIVE CARCINOMA;

ADULT; AGED; BREAST NEOPLASMS; CARCINOMA; COHORT STUDIES; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; LYMPHATIC METASTASIS; MIDDLE AGED; NEOPLASM METASTASIS; PROGNOSIS; RECURRENCE; RETROSPECTIVE STUDIES; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL;

EID: 79151474811     PISSN: 01676806     EISSN: 15737217     Source Type: Journal    
DOI: 10.1007/s10549-010-0855-6     Document Type: Article

References (36)

1. C Sotiriou L Pusztai 2009 Gene-expression signatures in breast cancer N Engl J 360 790 800 1:CAS:528:DC%2BD1MXitFWqs70%3D 10.1056/NEJMra0801289
2. CM Perou T Sorlie MB Eisen, et al. 2000 Molecular portraits of human breast tumours Nature 406 747 752 1:CAS:528:DC%2BD3cXmt1CnsLw%3D 10.1038/35021093 10963602
3. TO Nielsen FD Hsu K Jensen, et al. 2004 Immunohistochemical and clinical characterization of the basal-like subtype of invasive breast carcinoma Clin Cancer Res 10 5367 5374 1:CAS:528:DC%2BD2cXmvFSlt7k%3D 10.1158/1078-0432.CCR-04- 0220 15328174 (Pubitemid 39100473)
4. KR Bauer M Brown RD Cress CA Parise V Caggiano 2007 Descriptive analysis of estrogen receptor (ER)-negative, progesterone receptor (PR)-negative, and HER2-negative invasive breast cancer, the so-called triple-negative phenotype: a population-based study from the California cancer registry Cancer 109 1721 1728 10.1002/cncr.22618 17387718 (Pubitemid 46668532)
5. JS Reis-Filho AN Tutt 2008 Triple negative tumours: a critical review Histopathology 52 108 118 1:STN:280:DC%2BD1c%2FgsF2mtg%3D%3D 10.1111/j.1365-2559.2007.02889.x 18171422 (Pubitemid 350265179)
6. C Fan DS Oh L Wessels, et al. 2006 Concordance among gene-expression- based predictors for breast cancer N Engl J Med 355 560 569 1:CAS:528: DC%2BD28XotVKnur4%3D 10.1056/NEJMoa052933 16899776 (Pubitemid 44200649)
7. LG Fulford JS Reis-Filho K Ryder, et al. 2007 Basal-like grade III invasive ductal carcinoma of the breast: patterns of metastasis and long-term survival Breast Cancer Res 9 R4 10.1186/bcr1636 17217540 (Pubitemid 350215157)
8. M Kryj B Maciejewski HR Withers JM Taylor 1997 Incidence and kinetics of distant metastases in patients with operable breast cancer Neoplasma 44 3 11 1:STN:280:DyaK2szksV2jtQ%3D%3D 9201274
9. J Yokota 2000 Tumor progression and metastasis Carcinogenesis 21 497 503 1:CAS:528:DC%2BD3cXitVeitrY%3D 10.1093/carcin/21.3.497 10688870
10. HY Chang DS Nuyten JB Sneddon, et al. 2005 Robustness, scalability, and integration of a wound-response gene expression signature in predicting breast cancer survival Proc Natl Acad Sci 102 3738 3743 1:CAS:528:DC%2BD2MXisVOgtr4%3D 10.1073/pnas.0409462102 15701700 (Pubitemid 40354681)
11. HF Dvorak 1986 Tumors: wounds that do not heal, similarities between tumor stroma generation and wound healing N Engl J Med 315 1650 1659 1:STN:280:DyaL2s%2FmsV2mtw%3D%3D 10.1056/NEJM198612253152606 3537791
12. AH Beck I Espinosa CB Gilks M van de Rijn RB West 2008 The fibromatosis signature defines a robust stromal response in breast carcinoma Lab Invest 88 591 601 1:CAS:528:DC%2BD1cXmt1Sgt7s%3D 10.1038/labinvest.2008.31 18414401 (Pubitemid 351733278)
13. G Finak N Bertos F Pepin, et al. 2008 Stromal gene expression predicts clinical outcome in breast cancer Nat Med 14 518 527 1:CAS:528: DC%2BD1cXlsFCms7w%3D 10.1038/nm1764 18438415 (Pubitemid 351655218)
14. WE Mesker JM Junggeburt K Szuhai, et al. 2007 The carcinoma-stromal ratio of colon carcinoma is an independent factor for survival compared to lymph node status and tumor stage Cell Oncol 29 387 398 17726261
15. WE Mesker G Liefers JMC Junggeburt, et al. 2009 Presence of a high amount of stroma and downregulation of smad-4 predict a worse survival for stage I-II colon cancer patients Cell Oncol 31 169 178 1:CAS:528:DC%2BD1MXlsFWgs78%3D 19478385
16. LM McShane DG Altman W Sauerbrei SE Taube M Gion GM Clark 2006 REporting recommendations for tumor MARKer prognostic studies (REMARK) Breast Cancer Res Treat 100 229 235 10.1007/s10549-006-9242-8 16932852 (Pubitemid 44631925)
17. H Putter M Fiocco RB Geskus 2007 Tutorial in biostatistics: competing risks and multi-state models Stat Med 26 2389 2430 1:STN:280: DC%2BD2s3hs1agsA%3D%3D 10.1002/sim.2712 17031868 (Pubitemid 46730255)
18. EF Courrech Staal MW Wouters JW van Sandick, et al. 2010 The stromal part of adenocarcinomas of the oesophagus: does it conceal targets for therapy? Eur J Cancer 46 720 728 10.1016/j.ejca.2009.12.006 20044247
19. L Harris H Fritsche R Mennel, et al. 2007 American society of clinical oncology 2007 update of recommendations for the use of tumor markers in breast cancer J Clin Oncol 25 5287 5312 1:CAS:528:DC%2BD2sXhsVKnsbzK 10.1200/JCO.2007.14.2364 17954709 (Pubitemid 350232263)
20. J Thomas A Hanby S Pinder, et al. 2008 Implications of inconsistent measurement of ER status in non-invasive breast cancer: a study of 1, 684 cases from the Sloane project Breast J 14 33 38 10.1111/j.1524-4741.2007.00523.x 18186863
21. CB Nunes RM Rocha JS Reis-Filho, et al. 2008 Comparative analysis of six different antibodies against Her2 including the novel rabbit monoclonal antibody (SP3) and chromogenic in situ hybridisation in breast carcinomas J Clin Pathol 61 934 938 1:STN:280:DC%2BD1cvotVyqtA%3D%3D 10.1136/jcp.2007.053892 18474540
22. K Annecke M Schmitt U Euler, et al. 2008 uPA and PAI-1 in breast cancer: review of their clinical utility and current validation in the prospective NNBC-3 trial Adv Clin Chem 45 31 45 1:CAS:528:DC%2BD1cXmtF2isrY%3D 10.1016/S0065-2423(07)00002-9 18429492
23. MJ van de Vijver YD He LJ van't Veer, et al. 2002 A gene-expression signature as a predictor of survival in breast cancer N Engl J Med 347 1999 2009 10.1056/NEJMoa021967 12490681 (Pubitemid 35461656)
24. L Ein-Dor I Kela G Getz D Givol E Domany 2005 Outcome signature genes in breast cancer: is there a unique set? Bioinformatics 21 171 178 1:CAS:528:DC%2BD2MXkt1Wiuw%3D%3D 10.1093/bioinformatics/bth469 15308542 (Pubitemid 40202018)
25. S Michiels S Koscielny C Hill 2005 Prediction of cancer outcome with microarrays: a multiple random validation strategy Lancet 365 488 492 1:CAS:528:DC%2BD2MXhtlSgt7s%3D 10.1016/S0140-6736(05)17866-0 15705458 (Pubitemid 40215731)
26. B Haibe-Kains C Desmedt C Sotiriou G Bontempi 2008 A comparative study of survival models for breast cancer prognostication based on microarray data: does a single gene beat them all? Bioinformatics 24 2200 2208 1:CAS:528:DC%2BD1cXhtFOgs7%2FN 10.1093/bioinformatics/btn374 18635567
27. C Sotiriou MJ Piccart 2007 Taking gene-expression profiling to the clinic: when will molecular signatures become relevant to patient care? Nat Rev Cancer 7 545 553 1:CAS:528:DC%2BD2sXmvVakurc%3D 10.1038/nrc2173 17585334 (Pubitemid 46985399)
28. B Haibe-Kains C Desmedt F Piette, et al. 2008 Comparison of prognostic gene expression signatures for breast cancer BMC Genomics 9 394 10.1186/1471-2164-9-394 18717985
29. M Thomassen Q Tan F Eiriksdottir M Bak S Cold TA Kruse 2007 Comparison of gene sets for expression profiling: prediction of metastasis from low-malignant breast cancer Clin Cancer Res 13 5355 5360 1:CAS:528:DC%2BD2sXhtVCitL%2FL 10.1158/1078-0432.CCR-07-0249 17875763 (Pubitemid 47510360)
30. P Wirapati C Sotiriou S Kunkel, et al. 2008 Meta-analysis of gene expression profiles in breast cancer: toward a unified understanding of breast cancer subtyping and prognosis signatures Breast Cancer Res 10 R65 10.1186/bcr2124 18662380
31. M Buyse S Loi L Van't Veer, et al. 2006 Validation and clinical utility of a 70-gene prognostic signature for women with node-negative breast cancer J Natl Cancer Inst 98 1183 1192 1:CAS:528:DC%2BD28Xps1yjtLw%3D 10.1093/jnci/djj329 16954471 (Pubitemid 44390989)
32. K Polyak RA Weinberg 2009 Transitions between epithelial and mesenchymal states: acquisition of malignant and stem cell traits Nat Rev Cancer 9 265 273 1:CAS:528:DC%2BD1MXis1Chtb0%3D 10.1038/nrc2620 19262571
33. M Egeblad Z Werb 2002 New functions for the matrix metalloproteinases in cancer progression Nat Rev Cancer 2 161 174 1:CAS:528:DC%2BD38Xis1KktL8%3D 10.1038/nrc745 11990853
34. R Kalluri M Zeisberg 2006 Fibroblasts in cancer Nat Rev Cancer 6 392 401 1:CAS:528:DC%2BD28XjslGitLw%3D 10.1038/nrc1877 16572188
35. AF Olumi GD Grossfeld SW Hayward PR Carroll TD Tlsty GR Cunha 1999 Carcinoma-associated fibroblasts direct tumor progression of initiated human prostatic epithelium Cancer Res 59 5002 5011 1:CAS:528:DyaK1MXmslWktbc%3D 10519415
36. A Orimo PB Gupta DC Sgroi, et al. 2005 Stromal fibroblasts present in invasive human breast carcinomas promote tumor growth and angiogenesis through elevated SDF-1/CXCL12 secretion Cell 121 335 348 1:CAS:528:DC%2BD2MXktlSiu7w%3D 10.1016/j.cell.2005.02.034 15882617 (Pubitemid 40692295)